Aspergillosis - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Aspergillosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Aspergillosis - Pipeline Review, H1 2015', provides an overview of the Aspergillosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aspergillosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Aspergillosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Aspergillosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Aspergillosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Aspergillosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Aspergillosis Overview 9
Therapeutics Development 10
Pipeline Products for Aspergillosis - Overview 10
Pipeline Products for Aspergillosis - Comparative Analysis 11
Aspergillosis - Therapeutics under Development by Companies 12
Aspergillosis - Therapeutics under Investigation by Universities/Institutes 14
Aspergillosis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Aspergillosis - Products under Development by Companies 18
Aspergillosis - Products under Investigation by Universities/Institutes 20
Aspergillosis - Companies Involved in Therapeutics Development 21
Amplyx Pharmaceuticals, Inc. 21
Astellas Pharma Inc. 22
Aureogen Biosciences, Inc. 23
Basilea Pharmaceutica AG 24
Biomar Microbial Technologies 25
Eisai Co., Ltd. 26
F2G Ltd 27
iCo Therapeutics Inc. 28
MABLife S.A.S 29
Merck & Co., Inc. 30
Nanomerics Ltd 31
Novabiotics Ltd 32
Pulmocide Ltd 33
Scynexis, Inc. 34
Sealife PHARMA GMBH 35
Sigma-Tau S.p.A. 36
Vical Incorporated 37
Aspergillosis - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
amphotericin b - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
amphotericin B - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
amphotericin b NanoDisk - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ASP-2397 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASP-9726 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AUGC-10 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AUGC-15 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
C-001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
C-016 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
E-1210 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
E-1211 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
F-901318 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
FK506 Analogues - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GBV-042 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
isavuconazonium sulfate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KB-425796C - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MAT-401 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MDN-0018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NP-339 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
posaconazole - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PTX-3 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SCY-078 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SLP-0901 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SLP-0904 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Fungal Infections - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules for Fungal Infections - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules for Invasive Pulmonary Aspergillosis - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules to Inhibit ABC Transporter for Fungal Infections - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Aspergillosis - Recent Pipeline Updates 79
Aspergillosis - Dormant Projects 87
Aspergillosis - Dormant Projects 87
Aspergillosis - Discontinued Products 88
Aspergillosis - Product Development Milestones 89
Featured News & Press Releases 89
Apr 27, 2015: Astellas Launches CRESEMBA (isavuconazonium sulfate) in the United States for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 89
Apr 23, 2015: CRESEMBA (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases 89
Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas 90
Mar 06, 2015: FDA approves new antifungal drug Cresemba 91
Jan 22, 2015: Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis 92
Jan 09, 2015: SCYNEXIS Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections 93
Nov 21, 2014: Basilea Reports That U.S. FDA Sets Date Of Advisory Committee Meeting On Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Mucormycosis 93
Sep 09, 2014: F2G Announces A Major Funding Award From The Technology Strategy Board`s Biomedical Catalyst 93
Sep 06, 2014: Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis 94
Sep 05, 2014: Astellas to Showcase Isavuconazole Data at ICAAC 94
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables

Number of Products under Development for Aspergillosis, H1 2015 10
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2015 21
Aspergillosis - Pipeline by Astellas Pharma Inc., H1 2015 22
Aspergillosis - Pipeline by Aureogen Biosciences, Inc., H1 2015 23
Aspergillosis - Pipeline by Basilea Pharmaceutica AG, H1 2015 24
Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2015 25
Aspergillosis - Pipeline by Eisai Co., Ltd., H1 2015 26
Aspergillosis - Pipeline by F2G Ltd, H1 2015 27
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2015 28
Aspergillosis - Pipeline by MABLife S.A.S, H1 2015 29
Aspergillosis - Pipeline by Merck & Co., Inc., H1 2015 30
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2015 31
Aspergillosis - Pipeline by Novabiotics Ltd, H1 2015 32
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2015 33
Aspergillosis - Pipeline by Scynexis, Inc., H1 2015 34
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2015 35
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H1 2015 36
Aspergillosis - Pipeline by Vical Incorporated, H1 2015 37
Assessment by Monotherapy Products, H1 2015 38
Number of Products by Stage and Target, H1 2015 40
Number of Products by Stage and Mechanism of Action, H1 2015 42
Number of Products by Stage and Route of Administration, H1 2015 44
Number of Products by Stage and Molecule Type, H1 2015 46
Aspergillosis Therapeutics - Recent Pipeline Updates, H1 2015 79
Aspergillosis - Dormant Projects, H1 2015 87
Aspergillosis - Discontinued Products, H1 2015 88